ATE402168T1 - Heterocyclische topoisomerase toxine - Google Patents

Heterocyclische topoisomerase toxine

Info

Publication number
ATE402168T1
ATE402168T1 AT98965021T AT98965021T ATE402168T1 AT E402168 T1 ATE402168 T1 AT E402168T1 AT 98965021 T AT98965021 T AT 98965021T AT 98965021 T AT98965021 T AT 98965021T AT E402168 T1 ATE402168 T1 AT E402168T1
Authority
AT
Austria
Prior art keywords
sub
compounds
heterocyclic
group
salts
Prior art date
Application number
AT98965021T
Other languages
German (de)
English (en)
Inventor
Edmond Lavoie
Jun Kim
Leroy Liu
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Application granted granted Critical
Publication of ATE402168T1 publication Critical patent/ATE402168T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98965021T 1997-12-31 1998-12-30 Heterocyclische topoisomerase toxine ATE402168T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7028797P 1997-12-31 1997-12-31

Publications (1)

Publication Number Publication Date
ATE402168T1 true ATE402168T1 (de) 2008-08-15

Family

ID=22094368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98965021T ATE402168T1 (de) 1997-12-31 1998-12-30 Heterocyclische topoisomerase toxine

Country Status (11)

Country Link
US (3) US6667302B2 (enExample)
EP (1) EP1044199B1 (enExample)
JP (1) JP2002509858A (enExample)
CN (1) CN1299358A (enExample)
AT (1) ATE402168T1 (enExample)
AU (1) AU753268B2 (enExample)
CA (1) CA2316221A1 (enExample)
DE (1) DE69839781D1 (enExample)
IL (1) IL136911A0 (enExample)
PL (1) PL341539A1 (enExample)
WO (1) WO1999033824A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044199B1 (en) * 1997-12-31 2008-07-23 Rutgers, The State University Of New Jersey Heterocyclic topoisomerase poisons
US7511145B2 (en) * 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
AU2006204917A1 (en) * 2005-01-14 2006-07-20 Smithkline Beecham Corporation Indole derivatives for treating viral infections
EP1853590A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP2388263A1 (en) 2005-08-04 2011-11-23 Sirtris Pharmaceuticals, Inc. Imidazo[2,1-b]thiazole derivatives as sirtuin modulators
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2008073451A2 (en) * 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CA2747715A1 (en) 2008-12-19 2010-06-24 Sirtris Pharmaceuticals, Inc. Thiazolopyridine sirtuin modulating compounds
BR112017025241B1 (pt) 2015-05-28 2022-03-15 Ecolab Usa Inc Método e formulação para inibir a corrosão de uma superfície de metal em contato com um sistema aquoso
US10190222B2 (en) 2015-05-28 2019-01-29 Ecolab Usa Inc. Corrosion inhibitors
CN107667188B (zh) 2015-05-28 2020-10-30 艺康美国股份有限公司 基于嘌呤的腐蚀抑制剂
CA2987284C (en) 2015-05-28 2024-06-04 Ecolab Usa Inc. Water-soluble pyrazole derivatives as corrosion inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE26065E (en) 1966-07-19 Folybenzimidazoles and their preparation
US26065A (en) * 1859-11-08 Improvement in cotton-gins
US2985661A (en) 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole
CH420045A (de) 1964-09-01 1967-03-15 Ciba Geigy Verwendung von neuen Poly-azolen als optische Aufhellmittel für textile organische Materialien
DE1670684A1 (de) * 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
SU1530628A1 (ru) 1987-11-20 1989-12-23 Ленинградский Технологический Институт Им.Ленсовета Тригидрохлорид 2-[2-фенил-5(6)-бензимидазолил]-N-(3-диметиламинопропил)-5(6)-бензимидазолкарбоксамида в качестве флуоресцентного красител дл исследовани ДНК
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5807874A (en) 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
BR9608476A (pt) * 1995-05-17 1999-08-17 Univ Rutgers Composto processo para inibir o crescimento de uma célula tumoral de mam¡fero e composicão terapéutica
US5767142A (en) 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
EP1044199B1 (en) * 1997-12-31 2008-07-23 Rutgers, The State University Of New Jersey Heterocyclic topoisomerase poisons
IL137351A0 (en) * 1998-02-12 2001-07-24 Univ Rutgers Heterocyclic topoisomerase poisons

Also Published As

Publication number Publication date
IL136911A0 (en) 2001-06-14
AU753268B2 (en) 2002-10-10
US6995154B2 (en) 2006-02-07
US20040082637A1 (en) 2004-04-29
US20020151575A1 (en) 2002-10-17
JP2002509858A (ja) 2002-04-02
PL341539A1 (en) 2001-04-23
DE69839781D1 (en) 2008-09-04
CA2316221A1 (en) 1999-07-08
AU2022099A (en) 1999-07-19
EP1044199A1 (en) 2000-10-18
CN1299358A (zh) 2001-06-13
EP1044199B1 (en) 2008-07-23
US6667302B2 (en) 2003-12-23
US20080004280A1 (en) 2008-01-03
WO1999033824A1 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
ATE402168T1 (de) Heterocyclische topoisomerase toxine
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA200100983A1 (ru) Производные 13-метилэритромицина
DK1485359T3 (da) Natriumkanalblokkere
CY1111951T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
PT846686E (pt) Derivados de 1-fenil-pirazole e suas utilizacoes como agentes parasiticidas
EA200100135A1 (ru) Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
BR9801020A (pt) Derivados de azaindol-etilamina como agentes de ligação do receptor de acetilcolina nicotìnico.
ES2191260T3 (es) Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos.
EA200100422A1 (ru) Производные мононитрата изосорбида и их использование в качестве сосудорасширяющих агентов с пониженной толерантностью
EE200000472A (et) Kasvajavastased toimeained
ATE277062T1 (de) Neue makrolidderivate
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
DK1000034T3 (da) Substituerede 6-alkylphenanthridiner
DK1089625T3 (da) Ektoparasiticide midler
EP1453506A4 (en) Topoisomerase GIFT FUNDS
NO970340D0 (no) Organiske forbindelser
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren
BR0112957A (pt) Composto, método de tratamento, uso de um composto, e, composição farmacêutica
EA200101050A1 (ru) Замещенные бензолактамные соединения
ATE275558T1 (de) 4-arylpiperidinderivate zur behandlung von pruritus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties